Guardant Complete

Testing Across the
Continuum of Cancer

A comprehensive portfolio of liquid and tissue precision oncology tests for patients diagnosed with early or advanced-stage cancer.

Guardant 380

#1 Liquid Biopsy with a 100X Expanded Genomic and Epigenomic Footprint

Guardant360 Liquid CDx is the #1 liquid biopsy with the largest FDA-approved panel — featuring a 100x expanded genomic and epigenomic footprint vs. Guardant360 CDx.1,2 It is the only liquid biopsy with genome-wide methylation coverage, enabling deeper clinical insights and enhanced actionability within a 7-day turnaround time. Innovative, clinically actionable features powered by InfinityAI are available.3 Guardant360 Liquid CDx is guideline-recommended across advanced solid tumors and has broad commercial and Medicare coverage.4,5

Learn More About Guardant 360 Liquid CDx
Guardant360CDx product package

Guardant 360 CDx

A Fast CGP Panel With Guideline-Recommended Actionable Biomarkers

Guardant360 CDx is our FDA-approved liquid biopsy that provides results in less than 7 days to inform treatment decisions.4 Guardant360 CDx has broad commercial and Medicare coverage for all advanced solid tumors.5

Learn More About Guardant 360 CDx
Guardant 360 TissueNext

Guardant360 Tissue logo

The Most Advanced Tissue Test Integrating DNA, RNA, and Epigenomics

Guardant360 Tissue is the most advanced tissue test,6 integrating DNA, RNA, and epigenomics to deliver deep clinical insights with the lowest sample requirements. It requires 40% fewer slides7 and 92% less surface area8 than the industry standard. Innovative, clinically actionable features powered by InfinityAI are now available.3 Guardant360 Tissue has broad commercial and Medicare coverage for advanced solid tumors.9

Learn More About Guardant360 Tissue
Guardant Reveal Box
Guardant Reveal

Minimal Residual Disease Detection and Therapy Response Monitoring

Guardant Reveal is a simple blood test that utilizes circulating tumor DNA (ctDNA) to detect cancer at the molecular level, offering a more precise, ctDNA-guided approach to cancer monitoring. Guardant Reveal is available for molecular residual disease (MRD) detection and recurrence monitoring in early-stage colorectal, breast, and lung cancers and for therapy response monitoring in advanced cancer.10

Learn More About Guardant Reveal

Best-In-Class
Customer Service Offerings

Medical Affairs Support

On-demand medical experts to answer questions and guide clinical use of Guardant tests

Mobile Phlebotomy Services

An easy and convenience sample collection service that meets patients at their location

Guardant Access Program

Helps patients by minimizing surprise bills and checking eligibility for financial assistance

Digital Ordering with Guardant Portal and EMR Integrations

Simple paperless experience to speed up the ordering process

  1. Statement applies to G360 Liquid LDT as reported in a professional service report, which is part of Guardant360 Liquid CDx. The professional service report is not reviewed nor approved by the FDA. #1 liquid biopsy statement is based on stated brand utilization from a market research survey. Source: Guardant Health Data on file. Late-stage Chart Audit. April 2026
  2. Offered as a professional service. Not reviewed or approved by the FDA
  3. InfinityAI is not a standalone customer product. Product features “Powered by InfinityAI” are reported as professional services and have not been cleared or approved by the US FDA.
  4. Pending issuance of a dedicated CPT code for Guardant360 Liquid CDx, CPT code 0326U will be used to submit claims to commercial plans and managed care organizations. Guardant360 Liquid CDx is an FDA-approved test that meets the descriptor langauge for 0326U, which was established for our laboratory developed test that is substantially the same as Guardant360 Liquid CDx.
  5. In the event the test is not fully covered by insurance, patients may be eligible for financial assistance based on medical and financial need. To learn more, contact Guardant Health client services. For patients without insurance, the cash pay rate for Guardant360 Liquid CDx is $8,455 effective the first day of commercial launch, June 8, 2026
  6. Compared to the other leading comprehensive tissue tests. “Most advanced” refers to only tissue test delivering DNA, RNA and epigenomic results from a single sample output.
  7. 2mm2 for Guardant360 Tissue vs 25mm2 industry standard.
  8. 6 slides for Guardant360 Tissue vs 10-slide industry standard for NGS testing only.
  9. In the event the test is not fully covered by insurance, patients may be eligible for financial assistance based on medical and financial need. To learn more, contact Guardant Health client services. For patients without insurance, the cash pay rate for Guardant360 Tissue is $5,000 effective the first day of commercial launch April 28, 2025.
  10. In the event the test is not fully covered by insurance, patients may be eligible for financial assistance based on medical and financial need. To learn more, contact Guardant Health client services. For patients without insurance, the cash pay rate for Guardant Reveal is $3,500 effective the first day of commercial launch February 26, 2021.